K2M and International Spine Study Group Foundation Collaborate to Advance Data Management Using BACS®

LEESBURG, Va., Feb. 26, 2018 (GLOBE NEWSWIRE) — K2M Group Holdings, Inc. (NASDAQ:KTWO) (the “Company” or “K2M”), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance, today announced the licensure of its BACS® Data Management tool to the International Spine Study Group Foundation (ISSGF) for collecting spine patient data, including patient reported outcome measures (PROMs), as part of the ISSGF’s globally recognized research studies.

BACS Data Management is K2M’s cloud-based data collection and operative reporting system to track outcome metrics on surgical and non-surgical spine patients. These patients use tablets to report symptoms throughout their full episode of care, and surgeons can seamlessly input and analyze diagnostic data, surgical information, and radiographic imagery to better determine treatment specific to each patient.

“On behalf of the ISSGF, I am pleased that K2M’s BACS Data Management system will support our vision of translating clinical research into care of patients with many different spinal pathologies,” said Shay Bess, MD, founder and president of the ISSGF. “Effectively collecting and assessing clinical data is an important aspect for not only tracking patient outcomes, but also for identifying the most effective treatment options. K2M is an innovation leader in spine care and we are excited to partner with them in this effort.”

The ISSGF is a group of approximately 30 surgeons from around the world dedicated to the advancement of treatment for adults with spinal deformity. Members of the ISSGF practice at sites across the United States, Canada, and Japan, combining efforts to produce meaningful, cutting-edge research with the goal of advancing the evaluation, treatment, and outcomes for adult spinal deformity. The members constantly analyze the clinical applications of their research, working to put their findings into the context of improved patient care and outcomes. The ISSGF has presented more than 900 abstracts and published more than 200 manuscripts since the foundation was formed in 2010.

“K2M and the International Spine Study Group Foundation share a common belief—that advancements in spinal surgery increasingly come from technologies that let surgeons put the entire patient journey at the heart of treatment,” said K2M Chairman, President, and CEO Eric Major. “K2M continues to offer solutions to address the ever-changing healthcare landscape; K2M’s BACS Data Management allows the ISSGF to effectively and efficiently collect patient data as they develop predictive analytics models to help physicians tailor treatment approaches specific to each patient’s pathology.”

BACS Data Management is part of K2M’s comprehensive Balance ACS® (BACS) platform, which applies three-dimensional solutions across the entire clinical care continuum to help drive quality outcomes in spine patients. BACS provides solutions to help surgeons achieve balance of the spine by addressing each anatomical vertebral segment with a 360-degree approach to the axial, coronal, and sagittal planes, emphasizing Total Body Balance as an important component of surgical success.

For more information on K2M, visit www.K2M.com. For more information on Balance ACS, visit www.BACS.com.

About K2M

K2M Group Holdings, Inc. is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Since its inception, K2M has designed, developed, and commercialized innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal, and sagittal planes, with the goal of supporting the full continuum of care to facilitate quality patient outcomes. The Balance ACS platform, in combination with the Company’s technologies, techniques and leadership in the 3D-printing of spinal devices, enable K2M to compete favorably in the global spinal surgery market. For more information, visit www.K2M.com and connect with us on FacebookTwitterInstagramLinkedIn and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements that reflect current views with respect to, among other things, operations and financial performance.  Forward-looking statements include all statements that are not historical facts such as our statements about our expected financial results and guidance and our expectations for future business prospects.  In some cases, you can identify these forward-looking statements by the use of words such as, “outlook,” “guidance,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words.  Such forward-looking statements are subject to various risks and uncertainties including, among other things: our ability to achieve or sustain profitability in the future; our ability to demonstrate to spine surgeons the merits of our products and retain their use of our products; pricing pressures and our ability to compete effectively generally in our industry; collaboration and consolidation in hospital purchasing; inadequate coverage and reimbursement for our products from third-party payers; lack of long-term clinical data supporting the safety and efficacy of our products; dependence on a limited number of third-party suppliers; our ability to maintain and expand our network of direct sales employees, independent sales agencies and international distributors and their level of sales or distribution activity with respect to our products; proliferation of physician-owned distributorships in the industry; decline in the sale of certain key products; loss of key personnel; our ability to enhance our product offerings through research and development; our ability to manage expected growth; our ability to successfully acquire or invest in new or complementary businesses, products or technologies; our ability to educate surgeons on the safe and appropriate use of our products; costs associated with high levels of inventory; impairment of our goodwill and intangible assets; disruptions to our corporate headquarters and operations facilities or critical information technology systems, distributors or surgeon users; our ability to ship a sufficient number of our products to meet demand; our ability to strengthen our brand; fluctuations in insurance cost and availability; our ability to comply with extensive governmental regulation within the United States and foreign jurisdictions; our ability  to maintain or obtain regulatory approvals and clearances within the United States and foreign jurisdictions; voluntary corrective actions by us or our distribution or other business partners or agency enforcement actions; recalls or serious safety issues with our products; enforcement actions by regulatory agencies for improper marketing or promotion; misuse or off-label use of our products; delays or failures in clinical trials and results of clinical trials; legal restrictions on our procurement, use, processing, manufacturing or distribution of allograft bone tissue; negative publicity concerning methods of tissue recovery and screening of donor tissue; costs and liabilities relating to environmental laws and regulations; our failure or the failure of our agents to comply with fraud and abuse laws; U.S. legislative or Food and Drug Administration regulatory reforms; adverse effects of medical device tax provisions; potential tax changes in jurisdictions in which we conduct business; our ability to generate significant sales; potential fluctuations in sales volumes and our results of operations over the course of the year; uncertainty in future capital needs and availability of capital to meet our needs; our level of indebtedness and the availability of borrowings under our credit facility; restrictive covenants and the impact of other provisions in the indenture governing our convertible  senior notes and our credit facility;  continuing worldwide economic instability; our ability to protect our intellectual property rights; patent litigation and product liability lawsuits; damages relating to trade secrets or non-competition or non-solicitation agreements; risks associated with operating internationally; fluctuations in foreign currency exchange rates; our ability to comply with the Foreign Corrupt Practices Act and similar laws; our ability to implement and maintain effective internal control over financial reporting; potential volatility in our stock price; our lack of current plans to pay cash dividends; increased costs and additional regulations and requirements as a result of no longer qualifying as an emerging growth company as of December 31, 2017; potential dilution by the future issuances of additional common stock in connection with our incentive plans, acquisitions or otherwise; anti-takeover provisions in our organizational documents and our ability to issue preferred stock without shareholder approval; potential limits on our ability to use our net operating loss carryforwards; and other risks and uncertainties, including those described under the section entitled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC and our Quarterly Report filed with the SEC on November 1, 2017, as such factors may be updated from time to time in our periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov.  Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and our filings with the SEC.

We operate in a very competitive and challenging environment.  New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this release.  We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

The forward-looking statements made in this press release relate only to events as of the date on which the statements are made.  We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.  We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Unless specifically stated otherwise, our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions we may make.

Media Contact:

Zeno Group on behalf of K2M Group Holdings, Inc.
Christian Emering, 212-299-8985
Christian.Emering@ZenoGroup.com

Investor Contact:
Westwicke Partners on behalf of K2M Group Holdings, Inc.
Mike Piccinino, CFA, 443-213-0500
K2M@westwicke.com

Collagen Matrix Launches OssiMend® Spine and DuraMatrix® Dural Repair Products in Asia

OAKLAND, N.J.Feb. 26, 2018 /PRNewswire/ — Collagen Matrix, Inc., a leader in regenerative medicine and a global manufacturer of collagen and mineral based medical devices announced today its first entrance into the India market with two product lines, OssiMend® bone graft matrices from its Spine Business Unit and DuraMatrix® membranes from its Dural Repair Business Unit.

OssiMend® bone graft matrices are designed to provide a scaffold for a patient to grow new bone and are typically used in spinal fusion surgeries. DuraMatrix® dural repair products are engineered to provide a scaffold for brain and spinal cord host dura to naturally regenerate resulting in the protection, closure and repair of dural defects as well as providing leak resistance of cerebrospinal fluid.

Both of these product lines as well as others from the Collagen Matrix five business units—Dental, Spine, Orthopaedic, Dural Repair and Nerve Repair—have been developed with its six proprietary technologies. With a robust 20-year reputation of product innovation, the Collagen Matrix products have helped patients worldwide with over 7.5 million medical devices.

Collagen Matrix now has the opportunity to launch its innovative products into India with this recent Registration Certificate of approval from the Central Drugs Standard Control Organisation, Medical Device & Diagnostic Division of Government of India.

“This first approval in India, the seventh largest country in the world, establishes an opportunity for Collagen Matrix to grow in this market and extends the Collagen Matrix Spine and Dural Repair footprint into Asia. It is another strategic milestone that represents our company’s commitment to continuously advancing our international distribution capability,” said Bart J. Doedens, CEO. “These products are a premium addition to the spine and neurosurgical surgeons’ biologics toolboxes, and the India market aligns with our expansion strategy.”

Discover more about the Collagen Matrix Spine Solutions at www.CollagenMatrix.com/Products/Spine and Dural Repair Solutions at www.CollagenMatrix.com/Products/Dural-Repair.

About Collagen Matrix
Collagen Matrix, Inc., founded in 1997, delivers a full line of the highest-quality collagen and mineral based medical devices that support the body’s natural ability to regenerate. The Company currently manufactures finished medical devices in the areas of Dental, Spine, Orthopaedic, Dural Repair and Nerve Repair Surgery. The evolution of the Company’s leadership, proprietary technologies, manufacturing expertise and product portfolio has established a solid foundation for continued growth. Opportunities continue to exist for collaboration through Product Distribution, Product Development and Contract Manufacturing. More information about Collagen Matrix can be found at www.CollagenMatrix.com.

Contact: Margo Lane
201-405-1477
mlane@collagenmatrix.com

 

SOURCE Collagen Matrix, Inc.

Related Links

http://www.collagenmatrix.com

Bioventus to Co-Develop Next Generation Bone Allograft with LifeLink

February 26, 2018

DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologic solutions, has entered into an agreement with LifeLink Tissue Bank, a division of LifeLink Foundation, Inc. headquartered in Tampa, FL, to co-develop a next generation bone allograft solution for use in spine and trauma surgery. Terms of the agreement were not disclosed.

“Orthobiologics will continue to evolve to meet the needs of patients, surgeons and payers and Bioventus is pleased to begin work on the next generation of bone graft solutions with LifeLink,” said Tony Bihl, CEO of Bioventus. “This approach is consistent with our strategy to grow sales of our existing products in the surgical orthobiologics space and expand our offering with new product innovations.”

“The gift of tissue donation is invaluable and offers the opportunity to benefit so many patients in need,” said Jean Davis, President and CEO of LifeLink Foundation, Inc. “Companies like Bioventus are helping to further enhance the immeasurable impact of tissue donations by investing in R&D to bring new solutions to the market and we are excited for our research teams to collaborate together on this development initiative.”

About LifeLink:

LifeLink Foundation, an independent, non-profit community service organization is dedicated to the recovery and transplantation of organs and tissue. The Foundation is made up of five divisions: LifeLink Tissue Bank, which recovers and processes tissue for patients in need; LifeLink of Florida, LifeLink of Georgia, and LifeLink of Puerto Rico, three federally-certified organ procurement organizations; and LifeLink Transplantation Immunology Laboratory, which supports 15 organ-specific transplant programs. Additionally, the LifeLink Legacy Fund supports the LifeLink Foundation mission through patient assistance, research and programmatic grants to improve organ and tissue donation, and transplantation. Learn more about LifeLink Foundation at www.LifeLinkFoundation.org or LifeLink Tissue Bank at www.LifeLinkTB.org.

About Bioventus

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Orthobiologic products from Bioventus include offerings for bone healing, bone graft and knee osteoarthritis. Its EXOGEN Ultrasound Bone Healing System uses safe, effective low intensity pulsed ultrasound (LIPUS) to stimulate the body’s natural healing process. EXOGEN has been used to treat more than 1 million patients worldwide and numerous regulatory agencies including the FDA, Health Canada, BSI, TGA, Medsafe, UAE Ministry of Health and SFDA have granted their approval of the product. Today it is the leading bone healing system in the market with complaints for lack of efficacy averaging less than 1%.

Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.

Bioventus, the Bioventus logo and EXOGEN are registered trademarks of Bioventus LLC.

Contacts

Bioventus LLC
Thomas Hill, 919-474-6715
thomas.hill@bioventusglobal.com

Episurf Medical AB (publ) secures external financing of up to SEK 70 million and will issue free warrants to its existing shareholders

Episurf Medical AB (publ) (“Episurf”) has signed an agreement relating to a financing of up to SEK 70 million. The capital will be used for execution of the company’s growth strategy. The transaction is carried out through the issuance of convertible notes (the “Notes”) with warrants attached (the “Warrants”) in several tranches spread over 36 months (each a ”Tranche”). Episurf will receive SEK 7 million through the first Tranche. Existing shareholders will receive free warrants to protect them against dilution. The financing is conditioned upon the shareholders’ meeting resolving on a new authorization for issuance and the board of directors will propose to the annual shareholders’ meeting, which is to be held on 9 April 2018, to resolve such new authorization.

“We are happy to conclude this financing agreement as it puts Episurf Medical in a great position to execute on its strategy. We are continuing to report strong clinical results and as the Episealer® technology is gaining traction in Europe, we are just about to launch additional growth initiatives in US, Asia and in the Middle East.” comments Pål Ryfors, CEO, Episurf Medical.

The Tranches will be subscribed by European Select Growth Opportunities Fund (the “Investor”) which is a fund focusing on smallcap companies in the technology and healthcare sectors presenting a strong growth potential.

The financing relates to an issuance agreement entered into by Episurf with the Investor signed on the evening of 22 February 2018 (the “Agreement”). The first Tranche in the amount of SEK 7 million will be the first transaction pursuant to the Agreement.

In connection with the issue of the first Tranche of Notes and Warrants being carried out, which will occur subsequent to the annual general meeting 2018, Episurf will also issue free warrants to existing shareholders to protect them against dilution (the “Shareholders Warrants”). The Shareholders Warrants will be issued to Episurf’s subsidiary and thereafter be transferred to Episurf’s shareholders. The record date and the allocation proportion for the Shareholders Warrants will be announced at a later stage. The Shareholders Warrants will have the same characteristics as those of the Investor.

Highlights about the transaction:

  •  The first Tranche will be carried out as a directed issue of SEK 7 million through the issuance of Notes with Warrants attached to the Investor.
    •  Upon the full exercise of the Warrants and the Shareholders Warrants of the first Tranche Episurf will receive an additional SEK 7 million.
    •  Maximum additional potential financing of up to SEK 63 million (plus approximately SEK 63 million upon exercise of all the Warrants and the Shareholders Warrants) through similar directed issues in subsequent Tranches over the next 36 months, subject to fulfilment of certain conditions.
    •  As a technical measure in order to meet the Investor’s demand for immediate access to its shares, certain shareholders will, during a transitional period, lend shares to the issuing agent engaged for this Agreement.
      •  Episurf’s board of directors will propose to the annual shareholders’ meeting 2018 to resolve a new authorization for the board of directors so that the board of directors may be able to issue convertible notes and warrants. Provided that the shareholders’ meeting resolves on a new authorization, the board of directors will decide the issuance of the first Tranche under the Agreement as it is within the limitations of the company’s articles of association.

Main characteristics of the Notes, the Warrants and the Shareholders Warrants:

  •  The Notes have a principal amount of SEK 50,000 each. They bear no interest and have a maturity of 12 months from the date of the registration of their issuance with the Swedish Companies Registration Office. During their term, the Investor may request to convert some or all of the Notes at a variable conversion price representing an 8% discount to the lowest daily volume weighted average price over the last 15 trading days during which the Investor has not sold any share on the market prior to the conversion date (the “Reference Price”).
  •  Upon such conversion request, Episurf has the option to remit, at its discretion, cash, shares in Episurf or a combination of both. This characteristic will enable Episurf to manage the potential dilution resulting from the Notes.
  •  The Warrants have a term of five (5) years from the date of the registration of their issuance with the Swedish Companies Registration Office and will immediately be detached from the Notes. Each Warrant gives right to subscribe for one (1) new share (subject to standard adjustments in accordance with the terms and conditions of the Warrants) in Episurf at a fixed strike price representing a 120 % premium to the Reference Price on the date of the request from Episurf to issue a new Tranche.
  •  The strike price for Warrants under the first Tranche will be set at 120% of the lowest Reference Price on the following two dates: (i) the day of issuance of the first Tranche by the board of directors and (ii) 8 January 2018, the date of signature of the term sheet between Episurf and the Investor (being SEK 5.1132). Episurf will publicly announce the strike price of the Warrants in connection with the issuance of the first Tranche.
  •  The Shareholders Warrants will have the same characteristics as the Warrants and will be admitted to public trading.

Issuance of the subsequent Tranches

  •  Each subsequent Tranche will amount to SEK 7 million each (such amount may be increased upon mutual consent of the Investor and Episurf). Episurf will also issue Shareholders Warrants upon each subsequent Tranche.
  •  Episurf can require the Investor to subscribe a subsequent Tranche subject to the fulfillment of the following conditions on the date of the request and the date of funding of the requested Tranche:
    • all outstanding Notes have been completely converted or redeemed;
    • no material adverse change having occurred;
    • no event of default is in existence;
    • conversion of the Notes has not been prevented over the 90 preceding calendar days;
    • no suspension of trading of the shares having occurred over the 90 preceding calendar days;
    • The board of directors of Episurf is authorized to issue a sufficient number of shares for conversion of the Notes into shares and exercise of the Warrants;
    • the closing price and the daily volume weighted average price of the shares on each of the 10 preceding trading days is at least equal to SEK 4.00;
    • the average daily value traded of the shares over the 10 preceding trading days is at least equal to SEK 200,000;
    • post subscription of the requested Tranche, the Investor does not hold more than 7.5% of the then resulting outstanding number of shares of Episurf neither directly nor indirectly through the ownership of both shares and Notes.

The full terms and conditions of the Notes and the Warrants will be published on Episurf’s website, together with a follow-up table setting out information about the number of outstanding Notes, Warrants and Shares issued upon conversion of the Notes or exercise of the Warrants.

Example based on one Tranche:

  •  Issuance of Tranche:
    • Tranche amount: SEK 7,000,000
    • Tranche issuance Reference Price: SEK 5.70
    • Strike price of Warrants: SEK 5,70 * 120% ≈ SEK 6.84
    • Number of Notes: 7,000,000/50,000 = 140 Notes
    • Number of Warrants: 7,000,000 * 50% / 6.84 = 511,696
    • Number of additional Shareholders’ Warrants: 511,696 (100 % of number of Warrants to the Investor)
    •  Conversion of Notes:
      • Conversion Price: SEK 5.70 * 92% ≈ SEK 5.24
      • Number of shares: SEK 7,000,000/ SEK 5.24 = 1,335,877 shares
    •  Full exercise of warrants:
      • Investment from Investor’s Warrants at exercise: SEK 6.84 * 511,696 ≈ SEK 3,500,000
      • Investment from Shareholders’ Warrants at exercise: SEK 6.84 * 511,696 ≈ SEK 3,500,000
      • Total number of shares from warrants: 1,023,392
      • Total additional investment from warrants: SEK 7,000,000
    •  Dilution of shareholders per current number of shares from Notes and at full exercise of all warrants (the Investor’s and the shareholders’): ~7.17%

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.20 CET on 23 February 2018.

Ortho Sales Partners Announces Two Executive Additions and the Formation of Two Divisions (Orthopedics and Spine)

Ortho Sales Partners, the global leader in commercialization services for the orthopedic industry, is pleased to announce key additions allowing the formation of two separate divisions. This strategic move further demonstrates Ortho Sales Partners commitment to offer the industries most talented and experienced consultants to its clients. In advance of their presence at the American Academy of Orthopedic Surgeons annual conference (Booth 5713), Ortho Sales Partners announces the formation of two distinct divisions. One for Orthopedics and the other for Spine. Hired to lead the Orthopedic division are Jeff Chandler and Dan Darges.

Jeff Chandler, has been appointed General Manager of Orthopedics. Mr. Chandler has a rich history in commercializing products in Total Joint Reconstruction, Trauma and Sports Medicine. A key entrepreneurial career highlight featured Mr. Chandler as Founder & CEO/President of a venture capital backed medical device firm (Aquarius Medical), led the Company for six years incepting two core technologies (fluid management pump; core body thermoregulation from Stanford University OTL), and through product inventions (IP), funding, research, development, regulatory, manufacturing, commercialization, and into a successful exit.

About his joining Ortho Sales Partners, Jeff Chandler said: “I’m excited to bring a novel and cost-effective commercialization model to startup and emerging growth companies, or launching disruptive technologies for established medical device firms. In the entrepreneurial spirit of preserving expensive cash, OSP provides an attractive staged-based vehicle to deploy a multi-disciplined and highly networked senior level team in comparison to being confined by traditionally limited FTE hiring.”

Dan Darges, Vice President of Orthopedics, career started in 1997 with Smith & Nephew as a Ortho Recon/Trauma rep, Mr. Darges’ successes and reputation led him to accept an offer as a Regional Sales Director for a top Arthrex Distributorship in 2002.  Working for a Distributor allowed Mr. Darges to grow skills as a leader and manager for both Arthrex and Wright Medical product lines in Multiple States.  In 2007, Mr. Darges founded Bio-Surg Solutions, Inc., a Distributorship for Wright Medical.  After many successful years as one of the highest growth distributorships in the country, Mr. Darges sold his Distributorship to Wright Medical in 2012 and became a Senior Director of Sales for Wright Medical’s Foot and Ankle/Biologics products.

“I am really excited to be part of the Ortho Sales Partners team” said Darges. “I feel this role allows me to use my skill sets in multiple facets for multiple companies within the orthopedic industry.  I have enjoyed my time thus far as a consultant and look forward to taking on more responsibility for our clients as the Vice President of Orthopedics.”

For the spine division, Ortho Sales Partners has promoted Matt Stuttle to the position of General Manager. Mr. Stuttle has been in the medical industry for over 18 years. He began his career in spine in 2003 has held executive management positions at Kyphon (acquired by Medtronic in 2008 for $4.3B), Paradigm Spine, SpineWave and most recently Spineart.

“I feel strongly that Ortho Sales Partners is well positioned to facilitate guidance, structure, growth and scale to medical companies worldwide. Our strengths lie in our team; A world class organization of experienced executives across a broad spectrum of specialties, all designed to mitigate risk and speed execution. I’ve had the pleasure of knowing and working closely with Kevin over the last 15 years. His leadership and vast experience lends itself well to the core focus of Ortho Sales Partners; Creating immense value for our clients and their respective shareholders.”

As General Manager’s Jeff and Matt will report in to the CEO, Kevin McGann.

“We welcome Jeff and Dan to Ortho Sales Partners. As we continue to grow our business, it is important we structure and scale the organization that allows for the continued focus on our clients and positive outcomes. Having Matt and Jeff lead our Spine and Orthopedic Divisions will allow us to stay focused while utilizing their experience and leadership skills.”

About Ortho Sales Partners

Ortho Sales Partners has created a unique platform to help companies in any stage commercialize their products in a very efficient way. We have worked closely with many organizations and produced results that have profoundly impacted each client’s business.

Our services are geared to meet you where you are today and help your business grow by utilizing proven industry executives that bring you an objective analysis and recommendations going forward. Our market knowledge is based on current trends and competitive analysis from industry stalwarts from some of the highest growth companies.

Ortho Sales Partners’ headquarters are in Scottsdale, Arizona but we have several offices across the US. (http://www.orthosalespartners.com).

Medtronic Reports Third Quarter Financial Results

DUBLIN – February 20, 2108 – Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2018, which ended January 26, 2018.

The company reported third quarter worldwide revenue of $7.369 billion, an increase of 1 percent as reported, or 7 percent on a comparable, constant currency basis, which adjusts for the divestiture of its Patient Care, Deep Vein Thrombosis (Compression), and Nutritional Insufficiency businesses to Cardinal Health that occurred in the second quarter, and a $177 million positive impact from foreign currency.

As reported, third quarter GAAP net loss and loss per share (LPS) were $1.389 billion and $1.03, respectively. GAAP results included a $2.2 billion net charge primarily related to the U.S. transition tax charge as part of U.S. tax reform. As detailed in the financial schedules included through the link at the end of this release, third quarter non-GAAP net income and diluted EPS were $1.592 billion and $1.17, increases of 3 percent and 4 percent, respectively. Adjusting for the divestiture and a negative 1 cent impact from foreign currency, third quarter non-GAAP diluted EPS increased 12 percent.

Third quarter U.S. revenue of $3.912 billion represented 53 percent of company revenue and decreased 5 percent as reported, or increased 6 percent on a comparable basis. Non-U.S. developed market revenue of $2.355 billion represented 32 percent of company revenue and increased 7 percent as reported, or 5 percent on a comparable, constant currency basis. Emerging market revenue of $1.102 billion represented 15 percent of company revenue and increased 12 percent on both a reported and a comparable, constant currency basis.

“Our results reflect a solid quarter for Medtronic, and as we expected, a strong turnaround from the first half of our fiscal year,” said Omar Ishrak, Medtronic chairman and chief executive officer. “We continue to execute on our broad, sustainable growth strategy, driving therapy innovation and global market penetration, while delivering enterprise synergies to enable margin improvement.”

Cardiac and Vascular Group
The Cardiac and Vascular Group (CVG) includes the Cardiac Rhythm & Heart Failure (CRHF), Coronary & Structural Heart (CSH), and Aortic & Peripheral Vascular (APV) divisions. CVG worldwide third quarter revenue of $2.800 billion increased 10 percent, or 7 percent on a constant currency basis. CVG revenue performance was driven by strong, mid-teens growth in CSH and mid-single digit growth in CRHF and APV, all on a constant currency basis.

  • CRHF third quarter revenue of $1.457 billion increased 6 percent, or 4 percent on a constant currency basis. Arrhythmia Management grew in the low-single digits on a constant currency basis, driven by high-teens constant currency growth in AF Solutions, as well as strong adoption of the Micra® Transcatheter Pacing System and TYRX® absorbable antibacterial envelope. Heart Failure grew in the mid-single digits on a constant currency basis, driven by strong double digit constant currency growth in Mechanical Circulatory Support from sales of the HVAD(TM) System, as well as continued solid demand for the company’s portfolio of quadripolar cardiac resynchronization therapy pacemakers (CRT-P).
  • CSH third quarter revenue of $886 million increased 18 percent, or 14 percent on a constant currency basis, led by low-thirties constant currency growth in transcatheter aortic valves on the strength of the CoreValve® Evolut® PRO and U.S. intermediate risk indication. Coronary grew in the low-double digits on a constant currency basis, driven by strong demand for the company’s Resolute Onyx(TM) drug-eluting stent in the U.S. and Japan.
  • APV third quarter revenue of $457 million increased 7 percent, or 5 percent on a constant currency basis. Aortic grew in the low-single digits on a constant currency basis, driven by the performance of the Valiant® Captivia® thoracic stent graft system. Peripheral grew in the mid-single digits on a constant currency basis, driven by double digit growth in both PTA balloons and drug-coated balloons. High-single digit growth in endoVenous was driven by a strong performance of the VenaSeal(TM) closure system.

Minimally Invasive Therapies Group
The Minimally Invasive Therapies Group (MITG) includes the Surgical Innovations (SI) and the Respiratory, Gastrointestinal & Renal (RGR) divisions. MITG worldwide third quarter revenue of $2.041 billion decreased 16 percent as reported, or increased 6 percent on a comparable, constant currency basis. MITG revenue performance was driven by high-single digit growth in SI and low-single digit growth in RGR, both on a comparable, constant currency basis.

  • SI third quarter revenue of $1.384 billion increased 7 percent on a comparable, constant currency basis, driven by growth from new products in Advanced Energy and Advanced Stapling, including LigaSure(TM) vessel sealing instruments with nano-coating, endo stapling specialty reloads, and the Signia(TM) powered stapler.
  • RGR third quarter revenue of $657 million increased 3 percent on a comparable, constant currency basis. GI and Hepatology grew in the low-double digits on a comparable, constant currency basis, with strength across the GI therapeutics, diagnostics, and ablation product lines. Respiratory and Patient Monitoring grew in the low-single digits on a comparable, constant currency basis, with strength in Nellcor(TM) pulse oximetry sensors given the strong incidence of influenza in the U.S.

Restorative Therapies Group
The Restorative Therapies Group (RTG) includes the Spine, Brain Therapies, Specialty Therapies, and Pain Therapies divisions. RTG worldwide third quarter revenue of $1.944 billion increased 7 percent, or 5 percent on a constant currency basis. Group results were driven by low-double digit growth in Brain Therapies, high-single digit growth in Pain Therapies, and mid-single digit growth in Specialty Therapies, offsetting flat results in Spine, all on a constant currency basis.

  • Spine third quarter revenue of $661 million increased 1 percent, or was flat on a constant currency basis. Mid-single digit constant currency growth in bone morphogenetic protein (BMP) partially offset low-single digit declines in Core Spine, which were consistent with the Core Spine market.
  • Brain Therapies third quarter revenue of $585 million increased 13 percent, or 10 percent on a constant currency basis. Neurovascular grew in the high-teens on a constant currency basis, with strength across its stroke product portfolio. Neurosurgery grew in the low-double digits on a constant currency basis, led by strong sales of the StealthStation® S8 surgical navigation system and O-arm®2 surgical imaging system.
  • Specialty Therapies third quarter revenue of $398 million increased 8 percent, or 6 percent on a constant currency basis. High-single digit growth in Pelvic Health and ENT was partially offset by low-single digit declines in Transformative Solutions, all on a constant currency basis.
  • Pain Therapies third quarter revenue of $300 million increased 10 percent, or 8 percent on a constant currency basis. The division returned to growth on the strength of the recently launched Intellis(TM) platform for spinal cord stimulation, as well as growth in drug pumps.

Diabetes Group
The Diabetes Group includes the Intensive Insulin Management (IIM), Diabetes Service & Solutions (DSS), and Non-Intensive Diabetes Therapies (NDT) divisions. Diabetes Group worldwide third quarter revenue of $584 million increased 17 percent, or 13 percent on a constant currency basis. The group is experiencing strong global demand for its new sensor-augmented insulin pump systems, and has made great progress on its ability to meet this demand, as evidenced by the improved sequential revenue growth.

  • IIM third quarter revenue grew in the high-teens on a constant currency basis, driven by the U.S. launch of the MiniMed® 670G hybrid closed loop insulin pump system with the Guardian® sensor 3 CGM. In international markets, IIM delivered low-twenties constant currency growth on the continued strength of the MiniMed® 640G system.
  • DSS third quarter revenue grew in the mid-single digits on a constant currency basis, with growth in consumables benefitting from customer base growth and improved patient utilization.
  • NDT third quarter revenue declined in the mid-single digits on a constant currency basis, given the commercial focus on the MiniMed® 670G launch and competitive pressures.

Guidance
Medtronic today reiterated its fiscal year 2018 revenue and non-GAAP guidance. The company’s guidance is given on a comparable, constant currency basis, which accounts for the divestiture of certain businesses from its prior period Patient Monitoring & Recovery division by removing the financial impact of these businesses from the second, third, and fourth quarters of fiscal year 2017, as well as removing the impact of foreign currency.

In fiscal year 2018, the company continues to expect comparable, constant currency revenue growth to be in the range of 4 to 5 percent. While the impact of foreign currency remains fluid, if current exchange rates remain similar for the remainder of the fiscal year, the company’s revenue would be positively affected by approximately $480 million to $500 million for the fiscal year, including an approximate $300 to $320 million positive impact in the fourth fiscal quarter.

In fiscal year 2018, the company continues to expect diluted non-GAAP EPS growth to be in the range of 9 to 10 percent on a comparable, constant currency basis from the prior year comparable EPS of $4.37. Assuming current exchange rates remain similar for the rest of the year, the foreign exchange impact on the company’s non-GAAP EPS would be approximately negative 4 cents for the fiscal year, including an approximate 2 cent negative impact in the fourth fiscal quarter.

“Looking ahead, we are confident in our ability to deliver mid-single digit constant currency revenue growth and strong constant currency EPS leverage, this fiscal year and beyond,” said Ishrak. “We remain keenly focused on executing to deliver dependable results as we continue to leverage our global diversification and scale to fulfill our Mission of alleviating pain, restoring health, and extending life for millions of people around the world.”

Webcast Information
Medtronic will host a webcast today, February 20, at 8:00 a.m. EST (7:00 a.m. CST) to provide information about its businesses for the public, analysts, and news media. This quarterly webcast can be accessed by clicking on the Investor Events link at investorrelations.medtronic.com and this earnings release will be archived at newsroom.medtronic.com. Medtronic will be live tweeting during the webcast on our Newsroom Twitter account, @Medtronic. Within 24 hours of the webcast, a replay of the webcast and transcript of the company’s prepared remarks will be available by clicking on the Investor Events link at investorrelations.medtronic.com.

Financial Schedules
To view the third quarter financial schedules and non-GAAP reconciliations, click here. To view the third quarter earnings presentation, click here. Both documents can also be accessed by visiting newsroom.medtronic.com.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 84,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, which are subject to risks and uncertainties, including those described in Medtronic’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). Anticipated results only reflect information available to Medtronic at this time and may differ from actual results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release. Certain information in this press release includes calculations or figures that have been prepared internally and have not been reviewed or audited by our independent registered public accounting firm, including but not limited to, certain information in the financial schedules accompanying this press release. Use of different methods for preparing, calculating or presenting information may lead to differences and such differences may be material.

NON-GAAP FINANCIAL MEASURES
This press release contains financial measures and guidance, including growth rates on a comparable, constant currency basis and adjusted net income, and diluted EPS, which are considered “non-GAAP” financial measures under applicable SEC rules and regulations. References to quarterly figures increasing or decreasing are in comparison to the third quarter of fiscal year 2017.

Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company’s underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management’s review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.

Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking revenue growth and EPS projections exclude the impact of foreign currency fluctuations. Forward-looking non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, we believe such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

-end-

View FY18 Third Quarter Financial Schedules & Non-GAAP Reconciliations
View FY18 Third Quarter Earnings Presentation

Contacts:
Fernando Vivanco
Public Relations
+1-763-505-3780

Ryan Weispfenning
Investor Relations
+1-763-505-4626

Amplitude Surgical: Further Strong Organic Growth in Q2, +10% – H1 2017-18 Sales of €45 Million, +8%

VALENCE, France–(BUSINESS WIRE)–Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, PEA-PME eligible) (Paris:AMPLI), a leading French player on the global surgical technology market for lower-limb orthopedics, today announces its sales for the first half of its 2017-18 financial year.

Olivier Jallabert, Chairman and CEO of Amplitude Surgical, says: “Quarter after quarter, our growth is continuing at a strong pace. The successful implementation of our strategy, our international deployment with a portfolio of innovative products and the strong mobilization of our teams, will allow Amplitude Surgical to record sales in excess of €100 million this year. With double-digit growth in our subsidiaries and the upcoming launch of the commercialization of our hip and knee prostheses on the American market, our target of doubling our sales in 5 years (to June 2021) is on track”.

H1 2017-18 sales

31/12/2017 31/12/2016 Δ actual

Δ constant
currency

€ thousands – IFRS
France 28,019 25,923 8.1% 8.1%
International 16,643 15,960 4.3% 8.2%
of which: Subsidiaries 12,848 11,470 12.0% 17.5%
of which: Distributors 3,795 4,490 -15.5% -15.4%
Total 44,662 41,883 6.6% 8.1%

Q2 2017-18 sales

31/12/2017 31/12/2016 Δ actual

Δ constant
currency

€ thousands – IFRS
France 17,228 15,434 11.6% 11.6%
International 9,242 9,181 0.7% 6.2%
of which: Subsidiaries 6,779 6,376 6.3% 14.2%
of which: Distributors 2,463 2,805 -12.2% -12.1%
Total 26,471 24,615 7.5% 9.6%

Over the 1st half (July to December) of its 2017-18 financial year, Amplitude Surgical recorded sales of €44.7 million, up +6.6%. At constant currency, the increase was +8.1% over the first half and +9.6% over the second quarter, a significant acceleration compared with the +6.1% growth recorded in the first quarter.

The Group’s performance remained affected by a high basis for comparison (+19.8% at constant currency in H1 2016-17); thus, at constant currency, the average half-yearly growth over the last two years was close to +14%.

  • On the French market, half-year sales totaled €28 million, up +8.1%, with sales for the second quarter alone increasing by +11.6% to €17.2 million. This performance incorporates a 3.5% decrease applied to all implants in August 2017, on the initiative of the previous Health Minister (CEPS, the Economic Committee for Healthcare Products that governs pricing). Furthermore, the recent acquisition of commercial agents directly managing key regions in Eastern France and the Paris area will soon have a positive impact while enabling Amplitude Surgical to strengthen our sales presence in these regions.
  • The Group’s international activity also recorded solid growth over the half: +8.2% at constant currency to €16.7 million. This performance was driven by the growth of the Group’s subsidiaries, notably in Europe and in Australia, whose sales totaled €12.9 million, up 17.5% at constant currency, and accounted for 77% of international sales. Our distributors’ activity suffered from a very high basis for comparison (+65.5% in H1 2016-17) and thus fell -15.4%. Amplitude Surgical’s direct activity – the French market and international subsidiaries – increased by +11% at constant currency and accounted for almost 92% of total Group sales.
  • Novastep, which markets innovative solutions for extremities (foot and ankle) surgery, saw its sales continue to grow, notably in France (+38%), with international sales accounting for 60% of its total sales over the first half. Globally, 4 years after its first products were marketed, Novastep’s activity accounts for over 7% of Amplitude Surgical’s sales.

Moreover, Amplitude Surgical has a solid financial structure, with Cash & Cash Equivalents of almost €34 million at end-December 2017.

Upcoming event

Within the framework of establishing a sales network in the United States, Amplitude will again participate in the AAOS (American Academy of Orthopaedic Surgeons) Annual Meeting, from March 6 to 10, 2018 in New Orleans.

Next financial press release: H1 2017-18 results, on Wednesday March 28, 2018, after market.

About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. At June 30, 2017, Amplitude Surgical had a workforce of nearly 370 employees and recorded sales of over 93 million euros.

Contacts

Amplitude Surgical
Philippe Garcia, +33 (0)4 75 41 87 41
CFO
finances@amplitude-surgical.com
or
NewCap
Investor Relations
Marc Willaume, +33 (0)1 44 71 00 13
amplitude@newcap.eu
or
NewCap
Media Relations
Nicolas Merigeau, +33 (0)1 44 71 98 55
amplitude@newcap.eu

Centinel Spine and Performance Tech Announce Plan for a Season of Success

NEW YORK, Feb. 22, 2018 /PRNewswire/ — Centinel Spine, LLC is pleased to announce that it has extended an endorsement agreement with Performance Tech Motorsports for the entirety of the 2018 IMSA WeatherTech SportsCar Championship season. Centinel Spine first joined the Performance Tech family in January for the Rolex 24 At Daytona. This partnership will support the creation of a platform to educate the public on spinal disease and options that allow individuals to continue to function at a high level.

Centinel Spine, the pioneer of the No-Profile®, Integrated Interbody™ has a 30 year global clinical history of success behind these devices for treatment of degenerative disc disease. The company recently announced the acquisition of the worldwide assets of the prodisc® Total Disc Replacement portfolio. The prodisc line of products represents the most extensive total disc replacement (TDR) portfolio in the world with the longest history of use. The acquisition is the next step in the evolution of Centinel Spine executing on its mission to become the worldwide leading company addressing spinal disease through anterior access to the spine with the widest breadth and depth of technology platforms.

Performance Tech opens up a new type of athlete and patient population that Centinel Spine Chairman & CEO John Viscogliosi can reach and educate. Performance Tech and Team Principal Brent O’Neill are readily supplying athletes to Centinel Spine for examples of athleticism and the wear of high performance endurance.

“Centinel Spine is really an amazing company,” O’Neill said. “Everything they do to give people life after spinal disease is important. If you’re in a sport long enough or in racing long enough, you’ll have an injury and a lot of times it’s to the spine. This is as important to my drivers as it is my crew guys—you can’t do anything with a bad back. Having them as a sponsor is as much about helping a good cause as it is anything else. John and everyone at Centinel are great people and we’re excited to build something with them.”

Centinel Spine is making it an essential goal for 2018 to educate the public, not just the surgeons using its products. Viscogliosi has aligned the company with Performance Tech, as well as PGA Tour golfers, to help reach the masses. Performance Tech will play a primary role in creating the Centinel Spine platform. Viscogliosi is planning on learning as much from Performance Tech as he is educating.

“We are excited to extend our partnership with Performance Tech and continue to get the word out that Centinel Spine has solutions to address spine disease and to allow individuals get their lives back and function at a high level,” Viscogliosi. “The teamwork and commitment to excellence exhibited by the Performance Tech team at the Rolex 24 At Daytona last month confirmed that this is the right partnership to support our mission to raise awareness that spinal injury or disease does not need to result in a change in lifestyle. We are proud to be part of the Performance Tech family and look forward to working as a team to better educate race fans and the general public.”

Viscogliosi and O’Neill get to work this March for the Mobil 1 Twelve Hours of Sebring Presented by Advance Auto Parts. The race week begins Wednesday, March 14, with the crescendo coming at 10:40 a.m. and p.m. Saturday, March 17. The second installment of the Tequila Patròn North American Endurance Championship will air live on various FOX channels. Viewers can catch the start of the Twelve Hours of Sebring on FOX Sports 1 and the finish on FOX Sports 2.

About Centinel Spine, LLC.

Centinel Spine, LLC. is a privately-held spinal device company leading the development and commercialization of the No- Profile, Integrated Interbody fusion technologies. The company recently acquired the prodisc® Total Disc Replacement portfolio, an extensive cervical and lumbar disc replacement platform with the longest history of global clinical use. For more information on Centinel Spine products and technologies, please visit the Company’s website at www.CentinelSpine.com.

The Company began operations in August 2008, through the merger-acquisition of two pioneering medical device companies: Raymedica LLC and Surgicraft LTD. Today, Centinel Spine still embraces the pioneering culture developed at both originating companies and continues its corporate mission of becoming the leading anterior column reconstruction spine franchise, providing elegantly simple implants and instruments that are tissue-sparing and generate superior clinical outcomes.

Centinel Spine derived its name from the “Sentinel Sign” the radiographic confirmation of a successful fusion anterior to the interbody device.

For more information, please contact:

Varun Gandhi
SVP, Corporate Finance & Strategic Planning Centinel Spine, LLC
900 Airport Road, Suite 3B
West Chester, PA 19380
Phone: 484-887-8871
Email: v.gandhi@centinelspine.com

Wendy F. DiCicco
Chief Operating and Chief Financial Officer Centinel Spine, LLC
900 Airport Road, Suite 3B
West Chester, PA 19380
Phone: 484-887-8837
Email: w.dicicco@centinelspine.com

LBL 444 Rev 1 (02/2018)

SOURCE Centinel Spine

 

Related Links
http://www.centinelspine.com

Astura Medical Announces Initial Cases and Full Commercial Release For BRIDALVEIL OCT Stabilization System

CARLSBAD, CA – February 21, 2018 – Astura Medical, a high growth, innovative spine technology company, announced today the completion of the initial surgeries and full commercial release for its BRIDALVEIL Occipital-Cervico-Thoracic (OCT) System. The first cases were successfully completed at multiple hospitals across the country, including at the University of Colorado Hospital by Dr. David Ou-Yang, Assistant Professor of Orthopedics.

“Our practice addresses a wide range of complex conditions, so I’m always looking for the most advanced technology to meet our surgical demands,” said Dr. Ou-Yang. “Bridalveil OCT has not only met those demands, but it has continued to exceed my expectations. The versatility of the instrumentation, coupled with the breadth of implants offered has enhanced our ability to treat even the most complex cases. It is the most comprehensive and one of the most user friendly posterior cervical systems I’ve used from any company, large or small.”

“We are extremely proud of the feedback and success we’ve seen with Bridalveil OCT since our initial release of the system,” said Joel Gambrell, President and CEO of Astura Medical. “It allows us to continue to expand upon our goal of providing market leading technology to our growing network of surgeon and distributor partners.”

Designed with the most complex and demanding cases in mind, BRIDALVEIL OCT provides a comprehensive offering of screw options (single-lead, dual-lead, high-top, and smooth shank) ranging from 3.5mm to 5.5mm in diameter that are compatible with either a 3.5mm or 4.0mm rod in titanium or cobalt chrome. The system additionally provides an extensive line of connectors, transition rods, and instrumentation options to allow surgeons the ability to seamlessly transition across multiple segments of the spine.

About Astura Medical
Astura Medical was formed in 2014 with the objective of creating a disciplined, multi-phased approach to developing, manufacturing, and distributing medical devices. With surgeon input and feedback at every stage of development, Astura has created an extensive line of devices of the highest quality and sleekest design.

The two essential pillars that contribute to Astura Medical’s success are high quality products and robust distribution channels. These pillars, combined with passion and innovation, are what drive the Astura team to achieve great success with developing devices and entering them into the marketplace.

For more information, please visit www.asturamedical.com or find us on LinkedIn.

Media Contact:
Steve Haayen
Astura Medical
858.472.8825
steve@asturamedical.com

SeaSpine to Report Fourth Quarter and Full Year 2017 Financial Results on February 28, 2018

CARLSBAD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will release fourth quarter and full year 2017 financial results after the close of trading on Wednesday, February 28, 2018.  The Company’s management team will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET to discuss the financial results and recent business developments.

Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 7067009.  To listen to a live webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com.

The call will be archived until Thursday March 15, 2018. The audio archive can be accessed by calling (855) 859-2056 in the U.S. or (404) 537-3406 from outside the U.S. The passcode for the audio replay is 70677009.

About SeaSpine

SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.

Investor Relations Contact
Lynn Pieper
(415) 937-5402
ir@seaspine.com